Federated Hermes Inc. Has $85.40 Million Stake in Sanofi (NASDAQ:SNY)

Federated Hermes Inc. decreased its stake in Sanofi (NASDAQ:SNY) by 30.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,717,320 shares of the company’s stock after selling 755,840 shares during the quarter. Federated Hermes Inc. owned approximately 0.07% of Sanofi worth $85,402,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Rise Advisors LLC boosted its stake in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. SRS Capital Advisors Inc. raised its position in shares of Sanofi by 289.1% during the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after acquiring an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in shares of Sanofi during the third quarter worth $26,000. Fairfield Bush & CO. bought a new stake in shares of Sanofi during the first quarter worth $26,000. Finally, Salem Investment Counselors Inc. bought a new stake in shares of Sanofi during the fourth quarter worth $27,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on SNY shares. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Trading Down 1.6 %

NASDAQ SNY opened at $45.39 on Friday. The stock has a market capitalization of $114.82 billion, a price-to-earnings ratio of 19.23, a PEG ratio of 1.72 and a beta of 0.61. The stock’s 50 day moving average price is $47.52 and its two-hundred day moving average price is $48.67. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. As a group, analysts anticipate that Sanofi will post 4.15 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.